## Hindustan Unilever

## Volumes surge on focused brand building measures

Hindustan Unilever (HUL) clocked a strong 5\% growth in its volumes during Q3FY10 (up $1 \%$ QoQ). This, along with absence of price hikes, translated into a 4.6\% YoY growth in net sales to Rs 45 bn , in line with our estimates. The operating margin remained flat YoY as incremental savings in material costs were ploughed back as brand investments. The stock is likely to remain under pressure in the near-term due to regular price cuts taken by the company to augment volume growth. We therefore maintain Hold on the stock with a price target of Rs 257 , valuing it a $23 x$ its FY11E earnings.

Net sales in line with estimates: HUL's net sales for Q3FY10 increased by $4.6 \%$ YoY at Rs 45bn, in line with our estimate, entirely driven by higher volumes. Segment-wise, revenue growth was led by personal products (up 15.5\% YoY), beverages (up $7.9 \% \mathrm{YoY}$ ) and processed foods (up $9.2 \% \mathrm{YoY}$ ). The soaps \& detergents segment, however, slumped $2.4 \%$ YoY. Segments such as soaps, laundry, and personal products also booked higher volumes in the quarter, which were partly offset by price reductions in the laundry segment.

Margins remain flat: HUL's EBITDA grew $3.7 \%$ YoY to Rs 7.2 bn with an operating margin of $16 \%$ that remained flat YoY. The gross profit margin expanded 480bps YoY mainly on account of lower commodity prices and efficient cost management in sourcing raw materials. Bulk savings emanating from lower raw material costs were invested back by the company in the form of higher A\&P investments that grew $66 \%$ YoY to Rs 6.3 bn . A\&P expenses, as a percentage of sales, increased 530bps YoY to $14.1 \%$ while personnel and other expenses remained flat YoY.

Adj. PAT drops to Rs 6bn: HUL's reported PAT increased 5.4\% YoY to Rs 6.5 bn on account of profit on sale of properties. However, adjusting for exceptional items, adj. PAT declined $8.8 \%$ YoY to Rs 6 bn , lower than our estimate. Consequently, the adj. PAT margin also plunged 200bps YoY to $13.4 \%$.

Maintain Hold: Currently, HUL is trading at a P/E of 24.9x and 21.9x its FY10E and FY11E earnings. We have lowered our earnings estimates for FY10 and FY11 by $2.7 \%$ and $4.3 \%$ respectively. We have also downgraded our target P/E multiple from $24 x$ to $23 x$ to factor in the intensifying competition in the domestic FMCG space. Our price target also stands revised to Rs 257 (from Rs 274 previously). Maintain Hold.

| What's New? | Target | Rating | Estimates |
| :---: | :---: | :---: | :---: |
|  |  |  |  |
| CMP | TARGET | RATING | RISK |
| Rs 244 | Rs 257 | HOLD | LOW |
|  |  |  |  |
| BSE | NSE | BLOOMBERG |  |
| 500696 | HINDUNILVR | HUVR IN |  |

Company data

| Market cap (Rs mn / US\$ mn) | $532,905 / 11,540$ |
| :--- | ---: |
| Outstanding equity shares (mn) | 2,183 |
| Free float (\%) | 48 |
| Dividend yield (\%) | 3.2 |
| 52-week high/low (Rs) | $307 / 211$ |
| 2-month average daily volume | $2,988,908$ |

Stock performance

| Returns (\%) | CMP | 1-mth | 3-mth | 6-mth |
| :--- | ---: | ---: | ---: | ---: |
| HUL | 242 | $(8.6)$ | $(14.4)$ | $(9.7)$ |
| BSE FMCG | 2,725 | $(3.6)$ | $(3.6)$ | 5.5 |
| Sensex | 16,358 | $(6.0)$ | 1.9 | 7.8 |

## P/E comparison



Valuation matrix

| $(\mathbf{x})$ | FY09* | FY10E | FY11E | FY12E |
| :--- | ---: | ---: | ---: | ---: |
| P/E @ CMP | 21.3 | 24.9 | 21.9 | 19.7 |
| P/E @ Target | 22.4 | 26.2 | 23.0 | 20.7 |
| EV/EBITDA @ CMP | 19.4 | 19.6 | 17.4 | 15.9 |
| * 15 months period ending March 2009 |  |  |  |  |


| Financial highlights |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
| (Rs mn) | FY09* | FY10E | FY11E | FY12E |
| Revenue | 202,393 | 175,531 | 200,033 | 223,725 |
| Growth (\%) | 47.5 | $(13.3)$ | 14.0 | 11.8 |
| Adj net income | 25,007 | 21,435 | 24,386 | 27,061 |
| Growth (\%) | 34.3 | $(14.3)$ | 13.8 | 11.0 |
| FDEPS (Rs) | 11.5 | 9.8 | 11.2 | 12.4 |
| Growth (\%) | 34.0 | $(14.3)$ | 13.8 | 11.0 |

Profitability and return ratios

| (\%) | FY09* | FY10E | FY11E | FY12E |
| :--- | ---: | ---: | ---: | ---: |
| EBITDA margin | 13.2 | 15.1 | 14.9 | 14.6 |
| EBIT margin | 12.3 | 14.1 | 13.9 | 13.5 |
| Adj PAT margin | 12.4 | 12.2 | 12.2 | 12.1 |
| ROE | 142.9 | 100.6 | 107.1 | 79.1 |
| ROIC | 134.1 | 92.4 | 87.0 | 81.4 |
| ROCE | 125.7 | 84.1 | 88.4 | 68.9 |

## Result highlights

Fig 1 - Actual vs. estimated performance

| (Rs mn) | Actual | Estimate | \% Variance |
| :--- | ---: | ---: | ---: |
| Revenue | 45,043 | 45,662 | $(1.4)$ |
| EBITDA | 7,185 | 8,343 | $(13.9)$ |
| Adj net income | 6,046 | 6,702 | $(9.8)$ |
| FDEPS (Rs) | 2.77 | 3.07 | $(9.8)$ |
| Source: RHH |  |  |  |

Fig 2 - Quarterly performance

| (Rs mn) | Q3FY10 | Q3FY09 | \% Chg YoY | Q2FY10 | \% Chg QoQ |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Revenue | 45,043 | 43,077 | 4.6 | 42,281 | 6.5 |
| Expenditure | 37,857 | 36,147 | 4.7 | 36,172 | 4.7 |
| Operating profit | 7,185 | 6,931 | 3.7 | 6,110 | 17.6 |
| Other income | 1,079 | 1,045 | 3.2 | 884 | 22.0 |
| Interest | 2 | 44 | $(95.7)$ | 15 | $(87.0)$ |
| Depreciation | 450 | 406 | 10.9 | 462 | $(2.7)$ |
| PBT | 8,257 | 7,141 | 15.6 | 6,517 | 26.7 |
| Tax | 1,766 | 896 | 97.1 | 878 | 101.1 |
| PAT | 6,046 | 6,630 | $(8.8)$ | 4,287 | 41.1 |
| EBITDA margin (\%) | 16.0 | 16.1 | $(14 \mathrm{bps})$ | 14.4 | 150 bps |
| FDEPS (Rs) | 2.77 | 3.04 | $(9.0)$ | 1.97 | 40.8 |
| Source: Company, RHH |  |  |  |  |  |

Source: Company, RHH

Fig 3 - Revised estimates

| Key parameters | FY10E |  |  | FY11E |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| (Rs mn) | Old | New | \% Chg | Old | New | \% Chg |
| Revenue | 175,022 | 175,531 | 0.3 | 200,333 | 200,033 | $(0.1)$ |
| EBITDA | 25,156 | 26,558 | 5.6 | 29,682 | 29,897 | 0.7 |
| EBITDA margin (\%) | 14.4 | 15.1 | 76 bps | 14.8 | 14.9 | 13 bps |
| Net profit | 22,029 | 21,435 | $(2.7)$ | 25,495 | 24,386 | $(4.3)$ |
| FDEPS (Rs) | 10.10 | 9.82 | $(2.7)$ | 11.70 | 11.17 | $(4.3)$ |
| Source: RHH |  |  |  |  |  |  |

## Key highlights of the management conference call

* The domestic FMCG market has seen subdued growth primarily on account of lower prices in the laundry segment; this is attributed to the price cuts taken by the company. Downtrading in some segments like laundry and tea and high food price inflation has impacted demand for these products.
* Costs for commodities like palm oil, soda ash, LAB, and tea have firmed up.
* The company has seen volume growth in the laundry segment, both for powders and bars; however, value shares have declined on account of downtrading. Wheel powder has seen a 140bps improvement in market share with the share of Wheel bars surging 120bps on double-digit volume growth.
* The market share of HUL's soaps segment has improved 10bps QoQ on strong volume growth arising from the re-launch of Lux. Lifebuoy has still not attained the projected growth.
* In terms of Skin care, Fair \& Lovely, and Ponds have reported strong volume growth, led by the premium category. Fair \& Lovely (winter fairness) has also been successfully launched. The Vaseline winter range witnessed double-digit volume growth during the quarter.
* In terms of Hair care, Clinic Plus, and Dove led the volume growth through introduction of new variants. Sunsilk was also re-launched in November.
* The volumes for the oral care segment surged on account of the re-launch of Pepsodent and a pepper mint variant of Close-up.
* The growth in beverages was impacted due to lower growth in tea as downtrading by consumers impacted sales of Taaza and Red Label. HUL's market share in the tea segment was impacted due its absence in the discount segment. Therefore, the company has recently launched Brooke Bond Sehatmand in the discount segment to take advantage of the downtrading seen in this segment. For coffee, Bru Cappuchino has seen a good volume growth. The ice cream segment has also seen growth in the impulse and take-home categories.
* The company's gross margin has improved on account of benefits flowing in from better global scale, buying efficiencies, and lower commodity costs YoY.
* The company has recently taken some price cuts in the laundry segment, with prices of Rin lowered by $30 \%$ from Rs $70 / \mathrm{kg}$ to Rs $50 / \mathrm{kg}$ and prices of Surf Excel Blue reduced by $10 \%$ from Rs $91 / \mathrm{kg}$ to Rs $82 / \mathrm{kg}$.

Fig 4 - Value growth in soaps \& detergents continues to decline


Source: RHH, Company

Fig 5 - Value growth remains steady in personal products


Source: RHH, Company

Fig 6 - EBIT margin for soaps \& detergents remains suppressed


Source: RHH, Company

Fig 7 - EBIT margin for personal products remains stable YoY


Source: RHH, Company

## Standalone financials

Profit and Loss statement

| Y/E March (Rs mn) | FY09* | FY10E | FY11E | FY12E |
| :--- | ---: | ---: | ---: | ---: |
| Revenues | $\mathbf{2 0 2 , 3 9 3}$ | $\mathbf{1 7 5 , 5 3 1}$ | $\mathbf{2 0 0 , 0 3 3}$ | $\mathbf{2 2 3 , 7 2 5}$ |
| Growth (\%) | 47.5 | $(13.3)$ | 14.0 | 11.8 |
| EBITDA | $\mathbf{2 6 , 7 8 0}$ | $\mathbf{2 6 , 5 5 8}$ | $\mathbf{2 9 , 8 9 7}$ | $\mathbf{3 2 , 7 0 2}$ |
| Growth (\%) | 35.3 | $(0.8)$ | 12.6 | 9.4 |
| Depreciation \& amortisation | 1,953 | 1,828 | 2,185 | 2,497 |
| EBIT | 24,827 | 24,730 | 27,712 | 30,204 |
| Growth (\%) | 34.9 | $(0.4)$ | 12.1 | 9.0 |
| Interest | 253 | 362 | 415 | 445 |
| Other income | 5,678 | 3,470 | 4,373 | 5,386 |
| EBT | 30,251 | 27,837 | 31,670 | 35,145 |
| Income taxes | 5,244 | 6,403 | 7,284 | 8,083 |
| Effective tax rate (\%) | 17.3 | 23.0 | 23.0 | 23.0 |
| Extraordinary items | $(43)$ | - | - | - |
| Min into / inc from associates | - | - | - | - |
| Reported net income | 24,965 | 21,435 | 24,386 | 27,061 |
| Adjustments | $(43)$ | - | - | - |
| Adjusted net income | $\mathbf{2 5 , 0 0 7}$ | $\mathbf{2 1 , 4 3 5}$ | $\mathbf{2 4 , 3 8 6}$ | $\mathbf{2 7 , 0 6 1}$ |
| Growth (\%) | 34.3 | $(14.3)$ | 13.8 | 11.0 |
| Shares outstanding (mn) | $2,178.6$ | $2,178.6$ | $2,178.6$ | $2,178.6$ |
| FDEPS (Rs) (adj) | $\mathbf{1 1 . 5}$ | $\mathbf{9 . 8}$ | $\mathbf{1 1 . 2}$ | $\mathbf{1 2 . 4}$ |
| Growth (\%) | 34.0 | $(14.3)$ | 13.8 | 11.0 |
| DPS (Rs) | 7.5 | 7.9 | 8.9 | 9.9 |

## Cash flow statement

| Y/E March (Rs mn) | FY09* | FY10E | FY11E | FY12E |
| :--- | ---: | ---: | ---: | ---: |
| Net income + Depreciation | 22,137 | 26,792 | 23,620 | 26,883 |
| Non-cash adjustments | 2,669 | $(3,530)$ | 2,951 | 2,675 |
| Changes in working capital | $(3,289)$ | 4,017 | 1,825 | 757 |
| Cash flow from operations | 21,516 | 27,279 | 28,397 | 30,315 |
| Capital expenditure | $(6,295)$ | $(7,209)$ | $(6,859)$ | $(5,523)$ |
| Change in investments | 11,668 | - | - | - |
| Other investing cash flow | 1,926 | - | - | - |
| Cash flow from investing | 7,299 | $(7,209)$ | $(6,859)$ | $(5,523)$ |
| Issue of equity | 381 | 0 | 0 | 19,619 |
| Issue/repay debt | 3,334 | 606 | 727 | 31 |
| Dividends paid | $(16,766)$ | $(17,663)$ | $(20,391)$ | $(23,842)$ |
| Other financing cash flow | - | - | - | - |
| Change in cash \& cash eq | 15,765 | 3,014 | 1,874 | 20,599 |
| Closing cash \& cash eq | 17,773 | 20,787 | 22,661 | 43,260 |

## Economic Value Added (EVA) analysis

| Y/E March | FY09* | FY10E | FY11E | FY12E |
| :--- | ---: | ---: | ---: | ---: |
| WACC (\%) | 13.5 | 13.5 | 13.5 | 13.5 |
| ROIC (\%) | 134.1 | 92.4 | 87.0 | 81.4 |
| Invested capital (Rs mn) | 19,015 | 22,185 | 26,866 | 30,254 |
| EVA (Rs mn) | 22,934 | 17,521 | 19,758 | 20,564 |
| EVA spread (\%) | 120.6 | 79.0 | 73.5 | 68.0 |

Balance sheet

|  |  | FY09* | FY10E | FY11E |
| :--- | ---: | ---: | ---: | ---: | FY12E

## Financial ratios

| Y/E March | FY09* | FY10E | FY11E | FY12E |
| :---: | :---: | :---: | :---: | :---: |
| Profitability \& Return ratios (\%) |  |  |  |  |
| EBITDA margin | 13.2 | 15.1 | 14.9 | 14.6 |
| EBIT margin | 12.3 | 14.1 | 13.9 | 13.5 |
| Net profit margin | 12.4 | 12.2 | 12.2 | 12.1 |
| ROE | 142.9 | 100.6 | 107.1 | 79.1 |
| ROCE | 125.7 | 84.1 | 88.4 | 68.9 |
| Working Capital \& Liquidity ratios |  |  |  |  |
| Receivables (days) | 9 | 13 | 14 | 14 |
| Inventory (days) | 75 | 99 | 93 | 94 |
| Payables (days) | 104 | 141 | 142 | 142 |
| Current ratio (x) | 1.3 | 1.3 | 1.3 | 1.6 |
| Quick ratio (x) | 0.5 | 0.6 | 0.6 | 0.8 |
| Turnover \& Leverage ratios (x) |  |  |  |  |
| Gross asset turnover | 7.3 | 5.5 | 5.2 | 5.1 |
| Total asset turnover | 2.7 | 2.0 | 2.0 | 1.8 |
| Interest coverage ratio | 98.0 | 68.4 | 66.8 | 67.8 |
| Adjusted debt/equity | 0.2 | 0.2 | 0.2 | 0.1 |
| Valuation ratios (x) |  |  |  |  |
| EV/Sales | 2.6 | 3.0 | 2.6 | 2.3 |
| EV/EBITDA | 19.4 | 19.6 | 17.4 | 15.9 |
| P/E | 21.3 | 24.9 | 21.9 | 19.7 |
| P/BV | 25.8 | 24.2 | 22.6 | 11.9 |

Quarterly trend

| Particulars | Q4CY08 | Q1CY09 | Q1FY10 | Q2FY10 |
| :--- | ---: | ---: | ---: | ---: |
| Revenue (Rs mn) | 43,077 | 39,883 | 44,757 | 42,281 |
| YoY growth (\%) | 16.8 | 5.1 | 7.8 | 5.0 |
| QoQ growth (\%) | 6.9 | $(7.4)$ | 12.2 | 45,043 |
| EBITDA (Rs mn) | 6,931 | 5,493 | 6,881 | 6,110 |
| EBITDA margin (\%) | $1,608.9$ | $1,377.2$ | $1,537.4$ | $1,445.0$ |
| Adj net income (Rs mn) | 6,630 | 5,021 | 5,367 | 4,287 |
| YoY growth (\%) | 22.8 | 32.7 | $(3.9)$ | $(2.1)$ |
| QoQ growth (\%) | 51.4 | $(24.3)$ | 6.9 | $(20.1)$ |

DuPont analysis

| (\%) | CY07 | FY09* | FY10E | FY11E |  |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Tax burden (Net income/PBT) | $(5.0)$ | 28.6 | 15.4 | 15.4 |  |
| Interest burden (PBT/EBIT) | 123.8 | 121.9 | 112.6 | 114.3 | 15.4 |
| EBIT margin (EBIT/Revenues) | 13.4 | 12.3 | 14.1 | 13.9 | 196.4 |
| Asset turnover (Revenues/Avg TA) | 196.6 | 271.6 | 197.2 | 13.5 |  |
| Leverage (Avg TA/Avg equtiy) | 335.3 | 425.8 | 417.9 | 448.2 | $\mathbf{1 8 0 . 8}$ |
| Return on equity | $\mathbf{8 9 . 5}$ | $\mathbf{1 4 2 . 9}$ | $\mathbf{1 0 0 . 6}$ | $\mathbf{1 0 7 . 1}$ |  |

## Company profile

HUL, the largest FMCG Company in India (in terms of sales) has presence in soaps \& detergents, personal care products, beverages, foods and ice creams. HUL's primary strengths are strong brands and a wide distribution network with direct reach of over 1 mn retail outlets. This combined with the company's strengths in its business, its well developed distribution network; a strong brand portfolio will help it maintain market share.

## Recommendation history

| Date | Event | Reco price | Tgt price | Reco |
| :--- | :--- | :---: | :---: | :---: |
| 21-Aug-08 | RHH Compendium | 240 | 275 | Hold |
| 27-Oct-08 | Results Review | 224 | 260 | Hold |
| 28-Jan-09 | Results Review | 259 | 280 | Hold |
| 18-Mar-09 | Company Update | 234 | 280 | Buy |
| 11-May-09 | Results Review | 227 | 280 | Buy |
| 29-Jul-09 | Results Review | 268 | 280 | Hold |
| 2-Nov-09 | Results Review | 283 | 280 | Hold |
| 16-Dec-09 | Flash Note | 266 | 274 | Hold |
| 30-Jan-10 | Results Review | 244 | 257 | Hold |

Shareholding pattern

| $(\%)$ | Jun-09 | Sep-09 | Dec-09 |
| :--- | ---: | ---: | ---: |
| Promoters | 52.1 | 52.1 | 52.0 |
| Flls | 14.3 | 14.7 | 14.7 |
| Banks \& Fls | 14.9 | 14.3 | 14.3 |
| Public | 18.7 | 18.9 | 19.0 |

Stock performance


## Coverage Profile



Recommendation interpretation

| Recommendation | Expected absolute returns (\%) over 12 months |
| :--- | :--- |
| Buy | More than $15 \%$ |
| Hold | Between $15 \%$ and $-5 \%$ |
| Sell | Less than $-5 \%$ |

Recommendation structure changed with effect from March 1, 2009

Expected absolute returns are based on share price at market close unless otherwise stated. Stock recommendations are based on absolute upside (downside) and have a 12 -month horizon. Our target price represents the fair value of the stock based upon the analyst's discretion. We note that future price fluctuations could lead to a temporary mismatch between upside/downside for a stock and our recommendation.

## Religare Capital Markets Ltd

$4^{\text {th }}$ Floor, GYS Infinity, Paranjpe 'B' Scheme, Subhash Road, Vile Parle (E), Mumbai 400057.

## Disclaimer

This document is NOT addressed to or intended for distribution to retail clients (as defined by the FSA).
This document is issued by Religare Hichens, Harrison \& Co Plc ("Hichens") in the UK, which is authorised and regulated by the Financial Services Authority in connection with its UK distribution. Hichens is a member of the London Stock Exchange.
This material should not be construed as an offer or recommendation to buy or sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action or any other matter. The material in this report is based on information that we consider reliable and accurate at, and share prices are given as at close of business on, the date of this report but we do not warrant or represent (expressly or impliedly) that it is accurate, complete, not misleading or as to its fitness for the purpose intended and it should not be relied upon as such. Any opinion expressed (including estimates and forecasts) is given as of the date of this report and may be subject to change without notice.

Hichens, and any of its connected or affiliated companies or their directors or employees, may have a position in any of the securities or may have provided corporate finance advice, other investment services in relation to any of the securities or related investments referred to in this document. Our asset management area, our proprietary trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this briefing note.
Hichens accepts no liability whatsoever for any direct, indirect or consequential loss or damage of any kind arising out of the use of or reliance upon all or any of this material howsoever arising. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss.
This document is confidential and is supplied to you for information purposes only. It may not (directly or indirectly) be reproduced, further distributed to any person or published, in whole or in part, for any purpose whatsoever. Neither this document, nor any copy of it, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. If you have received this document in error please telephone Nicholas Malins-Smith on +44 (0) 2073824479.
"Religare Enterprises Limited proposes, subject to receipt of requisite approvals, market conditions and other considerations, to make a rights issue of its equity shares to its existing shareholders and has filed a draft letter of offer ("DLOF") with the Securities and Exchange Board of India ("SEBI"). The DLOF is available on the website of SEBI at www.sebi.gov.in as well as on the websites of the lead manager at www.enam.com. Investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the section titled "Risk Factors" of the DLOF."

